Eric A. Rose, MD is Chairman of the Broadview Strategic Advisory Board. As an academic physician and entrepreneur with interests in drug discovery, biodefense, clinical evaluative research and health policy. Since 2007, he is the Executive Vice President for Life Sciences at MacAndrews & Forbes and CEO of Siga Technologies, Inc., a developer of anti-viral drug directed at potential agents of bioterror.

In 2008, he assumed the chairmanship of the Department of Health Policy at the Mount Sinai School of Medicine. From 1994 through 2007, he served as Surgeon in Chief at New York-Presbyterian Hospital/Columbia and Chairman of the Department of Surgery at the Columbia University College of Physicians and Surgeons, where he held a distinguished professorship.

An accomplished heart surgeon, researcher and entrepreneur, Dr. Rose grew one of the nation’s premier departments of surgery while managing, investigating and developing complex medical technologies ranging from heart transplantation and novel approaches to Alzheimer’s disease to bioterrorism. He has authored or co-authored more than 300 scientific publications and has received more than $25 million in NIH support for his research.

Dr. Rose pioneered heart transplantation in children, performing the first successful pediatric heart transplant in 1984, and has investigated many alternatives to heart transplantation, including cross-species transplantation and man-made heart pumps. Siga has received more than $100 million in federal research support since he joined the company, developing anti-viral drugs for smallpox, dengue, and Lassa fever. He received both his undergraduate and medical degrees from Columbia University.